bismuth has been researched along with vonoprazan in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 14 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Lu, NH; Zhu, Y | 2 |
| Gisbert, JP; Lamarque, D; O'Connor, A; O'Morain, C | 1 |
| Graham, DY; Howden, CW | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Du, Q; Han, Y; Li, Y; Lou, G; Lu, L; Wang, Y; Yan, H; Ye, J | 1 |
| Huang, J; Lin, Y | 1 |
| Love, BL; Yunusa, I | 1 |
| Dang, YN; Gao, X; Li, LR; Li, WJ; Li, X; Qian, HS; Xu, XB; Yang, Z; Yuan, L; Zhang, GX; Zhang, M; Zhang, WF | 1 |
| Ding, YM; Duan, M; Han, ZX; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Mu, YJ; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 1 |
| Chen, HW; Liu, JJ; Lu, Y; Peng, X; Su, PZ; Wan, Y; Yao, JY; Yu, J; Zhang, M; Zhi, M | 1 |
| Fan, LL; Guo, Y; He, P; Hu, J; Lan, CH; Liu, YX; Mei, H; Pan, J; Su, NY; Sun, WJ; Wang, XW; Zhang, DK; Zou, PY | 1 |
| Chan, P; Cheung, K; Deng, Z; Han, S; Li, K; Li, Y; Luo, X; Lyu, T; Ni, L | 1 |
| Czerniak, R; Gu, L; Hu, C; Men, R; Miao, J; Tang, J; Wang, W; Wang, Y; Yang, L; Yoshida, N | 1 |
| Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
| Eiamsitrakoon, T; Graham, DY; Mahachai, V; Ratana-Amornpin, S; Sanglutong, L; Siramolpiwat, S | 1 |
3 review(s) available for bismuth and vonoprazan
| Article | Year |
|---|---|
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Treatment of Helicobacter pylori infection 2017.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Vitamins | 2020 |
10 trial(s) available for bismuth and vonoprazan
| Article | Year |
|---|---|
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2023 |
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Topics: Adult; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2023 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Thailand | 2023 |
3 other study(ies) available for bismuth and vonoprazan
| Article | Year |
|---|---|
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rifabutin; Treatment Outcome; United States | 2023 |